Back to Results
First PageMeta Content
Medicine / In vitro fertilisation / Ovarian hyperstimulation syndrome / Gonadotropin-releasing hormone antagonist / Follicle-stimulating hormone / Transvaginal oocyte retrieval / Ovulation / Gonadotropin-releasing hormone / Ovarian hyperstimulation / Human reproduction / Fertility medicine / Fertility


Corifollitropin alfa (Elonva® in Daily Clinical Practice) Schenk M Journal für Gynäkologische Endokrinologie 2013; 7 (1)
Add to Reading List

Document Date: 2014-01-31 13:58:53

Open Document

File Size: 390,33 KB

Share Result on Facebook

City

Dobl / /

Company

Bilddatenbank / Datenbank / Verbrauchsmaterialien Gynemed GmbH / Kairos Life Science GmbH / Philips Clear Vue 650 Mides GmbH / Online-Datenbank / Medizintechnik-Produkte P MediTEX IVF Critex GmbH / Artikeldatenbank / HP / Inkubator Labotect GmbH / Origio GmbH / Xario 200 Toshiba Medical Systems / OvulaRing Gynial GmbH / MAS Chief Physician Das Kinderwunsch Institut Schenk GmbH / /

Country

Austria / /

Event

FDA Phase / Product Release / /

Facility

IVF Institute / /

IndustryTerm

antagonist protocol / authorization study protocols / stimulation protocol / internal treatment protocols / fixed antagonist protocol / pen device / therapeutic protocol / /

MedicalTreatment

embryo transfer / treatment protocols / ICSI / Ovulation induction / Hormone therapy / ovarian stimulation / intracytoplasmic sperm injection / in vitro fertilization / /

Organization

IVF Institute / Homepage / Das Kinderwunsch Institut / Austrian IVF Society / /

Person

Michael Schenk / /

Position

MAS Chief Physician / /

Product

FSH injections / iPad / GnRH / Elonva / Elonva® / /

Technology

internal treatment protocols / fixed antagonist protocol / stimulation protocol / ultrasound / GnRH antagonist protocol / marketing authorization study protocols / PDF / /

URL

www.kinderwunsch-institut.at / www.kup.at/gynaekologie / /

SocialTag